Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 4/20 | 0.42 |
| ▸ | CDC25B | P30305 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812363 | 0.82 | CYP1A2 (0.60) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL1269455 | 0.81 | KMT2A (0.58) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL538425 | 0.81 | HPGD (0.58) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL5422717 | 0.81 | KDM4E (0.58) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL5179019 | 0.79 | MEN1 (0.56) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL28535619 | 0.79 | KMT2A (0.56) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL8460754 | 0.77 | MEN1 (0.58) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL27363504 | 0.77 | MEN1 (0.53) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL8464718 | 0.77 | MEN1 (0.53) | KMT2AHPGDMEN1KDM4EALDH1A1 | |
| SCHEMBL497405 | 0.75 | KMT2A (0.66) | KMT2AHPGDMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363993-A4 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | BRISTOL MYERS SQUIBB CO (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1325009-B1 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960585-B2 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-6869956-B2 | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1363993-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1325009-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-30 | — | — | US | disclosed |
| WO-2002060386-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| WO-2002028860-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | IL4, IL4I1, MSR1 | KMT2A 2115/4885HPGD 2777/4885MEN1 4334/4885 |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | NFKBIA, IKBKG, IKBKB | KMT2A 616/4885HPGD 1035/4885MEN1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.